Liquid biopsies come of age: towards implementation of circulating tumour DNA
- PMID: 28233803
- DOI: 10.1038/nrc.2017.7
Liquid biopsies come of age: towards implementation of circulating tumour DNA
Abstract
Improvements in genomic and molecular methods are expanding the range of potential applications for circulating tumour DNA (ctDNA), both in a research setting and as a 'liquid biopsy' for cancer management. Proof-of-principle studies have demonstrated the translational potential of ctDNA for prognostication, molecular profiling and monitoring. The field is now in an exciting transitional period in which ctDNA analysis is beginning to be applied clinically, although there is still much to learn about the biology of cell-free DNA. This is an opportune time to appraise potential approaches to ctDNA analysis, and to consider their applications in personalized oncology and in cancer research.
Similar articles
-
Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.Lung Cancer. 2017 Sep;111:135-138. doi: 10.1016/j.lungcan.2017.06.015. Epub 2017 Jun 23. Lung Cancer. 2017. PMID: 28838384
-
How liquid biopsies can change clinical practice in oncology.Ann Oncol. 2019 Oct 1;30(10):1580-1590. doi: 10.1093/annonc/mdz227. Ann Oncol. 2019. PMID: 31373349 Review.
-
Circulating tumor DNA as a liquid biopsy for cancer.Clin Chem. 2015 Jan;61(1):112-23. doi: 10.1373/clinchem.2014.222679. Epub 2014 Nov 11. Clin Chem. 2015. PMID: 25388429 Review.
-
Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?Expert Rev Mol Diagn. 2017 Dec;17(12):1089-1096. doi: 10.1080/14737159.2017.1395701. Epub 2017 Nov 14. Expert Rev Mol Diagn. 2017. PMID: 29057681 Review.
-
Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.Mol Oncol. 2016 Mar;10(3):464-74. doi: 10.1016/j.molonc.2015.12.001. Epub 2015 Dec 17. Mol Oncol. 2016. PMID: 26776681 Free PMC article. Review.
Cited by
-
Perioperative Use of ctDNA to Guide Treatment for Urothelial Carcinoma: The Future is Now.Bladder Cancer. 2024 Oct 23;10(3):183-198. doi: 10.3233/BLC-230105. eCollection 2024. Bladder Cancer. 2024. PMID: 39493820 Free PMC article. Review.
-
Applying the concept of liquid biopsy to monitor the microbial biodiversity of marine coastal ecosystems.ISME Commun. 2022 Jul 27;2(1):61. doi: 10.1038/s43705-022-00145-0. ISME Commun. 2022. PMID: 37938655 Free PMC article.
-
Drivers of dynamic intratumor heterogeneity and phenotypic plasticity.Am J Physiol Cell Physiol. 2021 May 1;320(5):C750-C760. doi: 10.1152/ajpcell.00575.2020. Epub 2021 Mar 3. Am J Physiol Cell Physiol. 2021. PMID: 33657326 Free PMC article. Review.
-
Clinical application of molecular residual disease detection by circulation tumor DNA in solid cancers and a comparison of technologies: review article.Cancer Biol Ther. 2023 Dec 31;24(1):2274123. doi: 10.1080/15384047.2023.2274123. Epub 2023 Nov 13. Cancer Biol Ther. 2023. PMID: 37955635 Free PMC article. Review.
-
Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine.Chem Rev. 2024 Oct 23;124(20):11242-11347. doi: 10.1021/acs.chemrev.4c00244. Epub 2024 Oct 8. Chem Rev. 2024. PMID: 39380213 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical